Over 2 million children worldwide are living with HIV infection and 95% reside in sub-Saharan Africa with the majority infected through mother-to-child transmission. Infected children have a high mortality with 50% dying by 2 years of age. Their clinical presentation includes common childhood infect...ions, opportunistic infections and conditions associated with HIV/AIDS immune suppression.
more
Objective: The study aimed to describe the current epidemiological, clinical and immunological profile of newly
detected HIV - positive patients in Northern Benin by 2016. Methods: It was a prospective study conducted from May 2 to
October 31, 2016 on three main sites of care of people living with... HIV (PLHIV) in the department of Borgou in Benin. All
new cases of HIV infection have been systematically and comprehensively recruited. Initial epidemiological, clinical and
immunological data were collected using a questionnaire. These data were entered and analyzed using the Epi Info 7 software.
Results: In total, 185 adults (68 male and 117 female) newly screened HIV positive were included in this study. The middle age
was 36.2 ± 10.9 years and the sex ratio was 0.6 One hundred and thirty-five patients (73%) were between 25 and 50 years old.
In terms of the profession, 132 patients (71.3%) were engaged in liberal activities (craftmen, traders and retailers). The
majority was schooled (113 or 61.1%) and resided in urban areas (146 or 79%). One hundred and sixteen patients lived in
couple (62.7%) with an average monthly income estimated at 70 US Dollars. Clinically, 123 patients (66.5%) were in WHO
stage III. The body mass index was over 18.5 kg/m2 in 124 patients (67%). The median number of TCD4 lymphocytes was
254.5 cells/ml and 25 patients (13.5%) had a number of CD4 over 500 cells/ml. HIV1 was really predominant (97.8%). Most
patients (152 or 82.2%) had been screened for clinical suspicion. Conclusion: HIV infection in Benin remains the prerogative
of young, female, educated and poor people. Screening is delayed and hence the need to develop innovative strategies for early
more
Epidemiology
Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or... drink.1-4 The hematophagous triatomine vectors defecate during or immediately after feeding on a person. The parasite is present in large numbers in the feces of infected bugs, and enters the human body through the bite wound, or through the intact conjunctiva or other mucous membrane.
Vector-borne transmission occurs only in the Americas, where an estimated 8 to 10 million people have Chagas disease.5 Historically, transmission occurred largely in rural areas in Latin America, where houses built of mud brick are vulnerable to colonization by the triatomine vectors.4 In such areas, Chagas disease usually is acquired in childhood. In the last several decades, successful vector control programs have substantially decreased transmission rates in much of Latin America, and large-scale migration has brought infected individuals to cities both within and outside of Latin America.
more
The goal of this addendum is to help management and staff
minimize the risk of TB transmission at facilities in resource limited settings in which a.) HIV-infected persons receive diagnosis, care, treatment,
and/or support, and b.) there is a high prevalence of HIV infection, both known
and... undiagnosed, in settings such as prisons, jails, other
detention centers, and drug rehabilitation centers.
more
Dispatches
DOI: http://dx.doi.org/10.3201/eid2203.151607
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 3, March 2016
Rueda S, et al. BMJ Open 2016;6:e011453. doi:10.1136/bmjopen-2016-011453
Tropical Medicine and International Health volume 21 no 1 pp 101-107 january 2016
A Systematic Review and Meta-analysis
Clinical Infectious Diseases® 2016;62(12):1586–94
This operational guidance provides a structured approach to support countries in sustaining priority services for HIV, viral hepatitis and sexually transmitted infections in the context of reduced external funding. The guidance is intended for national governments, public health programmes, communit...y-led organizations, civil society, technical partners and donors working to safeguard priority services, support phased adaptation, protect health outcomes and preserve hard-won gains.
more
Participant Manual September 2012
Surveillance of Populations at High Risk for HIV Transmission
UNAIDS 2016 / Meeting Report
For the global community to be able to achieve ambitious targets relating to the prevention and treatment of HIV, viral hepatitis and sexually transmitted infections (STIs), multiple types of medicines must be widely accessible to all affected populations in all countries.
The purpose of this rep...ort is to provide forecasts of future demand for medicines used in the fields of HIV, viral hepatitis and STIs. This report jointly presents medicines forecasts across three disease areas in recognition of the benefits of addressing HIV, viral hepatitis and STIs in a coordinated manner.
more
This document highlights the latest WHO recommendations designed to optimize health outcomes, streamline delivery and address persistent barriers to prevention and care. It especially focuses on people often left behind in service delivery, including adolescents and young people, key populations and... people with advanced HIV disease. The guidance emphasizes integration, simplification, choice and equity.
more
Clinical Infectious Diseases
1586 - 1594 • CID 2016:62 (15 June) • HIV/AIDS
People Who Inject Drugs
In addition, the following individuals of our external expert advisory committee made instrumental contributions to the initial design and content of the document: Billy Pick, USAID; Daniel Wolfe, Open Society Foundations; Dave Burrows, AIDS Projects Management Group; Fabi...enne Hariga, United Nations Office on Drugs and Crime; Mauro Guarinieri, the Global Fund to Fight AIDS, Tuberculosis and Malaria; Richard Needle, Office of the U.S. Global AIDS Coordinator; and Sergey Votyagov, EHRN.
more